Bifogade filer
240815 Mendus 2Q 2024 Invite ENG
Kurs
+1,91%
Likviditet
0,19 MSEK
Prenumeration
Kalender
| Tid* | ||
| 2025-05-09 | N/A | Årsstämma |
| 2025-02-13 | 08:00 | Bokslutskommuniké 2024 |
| 2024-11-08 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-23 | - | Kvartalsrapport 2024-Q2 |
| 2024-06-03 | - | Split IMMU 20:1 |
| 2024-05-20 | - | X-dag ordinarie utdelning IMMU 0.00 SEK |
| 2024-05-17 | - | Årsstämma |
| 2024-05-17 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-14 | - | Bokslutskommuniké 2023 |
| 2023-12-13 | - | Extra Bolagsstämma 2023 |
| 2023-11-09 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-29 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-15 | - | X-dag ordinarie utdelning IMMU 0.00 SEK |
| 2023-05-12 | - | Årsstämma |
| 2023-05-12 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-17 | - | Bokslutskommuniké 2022 |
| 2022-11-18 | - | Extra Bolagsstämma 2022 |
| 2022-11-11 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-26 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-11 | - | X-dag ordinarie utdelning IMMU 0.00 SEK |
| 2022-05-10 | - | Årsstämma |
| 2022-05-10 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-17 | - | Bokslutskommuniké 2021 |
| 2021-10-28 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-26 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-05 | - | X-dag ordinarie utdelning IMMU 0.00 SEK |
| 2021-05-04 | - | Årsstämma |
| 2021-05-04 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-18 | - | Bokslutskommuniké 2020 |
| 2021-01-22 | - | Extra Bolagsstämma 2021 |
| 2020-12-18 | - | Extra Bolagsstämma 2020 |
| 2020-11-05 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-27 | - | Kvartalsrapport 2020-Q2 |
| 2020-04-29 | - | X-dag ordinarie utdelning IMMU 0.00 SEK |
| 2020-04-28 | - | Årsstämma |
| 2020-04-28 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-18 | - | Bokslutskommuniké 2019 |
| 2019-11-06 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-20 | - | Kvartalsrapport 2019-Q2 |
| 2019-04-26 | - | X-dag ordinarie utdelning IMMU 0.00 SEK |
| 2019-04-25 | - | Årsstämma |
| 2019-04-25 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-15 | - | Bokslutskommuniké 2018 |
| 2018-11-07 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-17 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-04 | - | Kvartalsrapport 2018-Q1 |
| 2018-04-26 | - | X-dag ordinarie utdelning IMMU 0.00 SEK |
| 2018-04-25 | - | Årsstämma |
| 2018-02-16 | - | Bokslutskommuniké 2017 |
| 2017-12-04 | - | Extra Bolagsstämma 2017 |
| 2017-11-17 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-18 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-19 | - | Kvartalsrapport 2017-Q1 |
| 2017-04-27 | - | X-dag ordinarie utdelning IMMU 0.00 SEK |
| 2017-04-26 | - | Årsstämma |
| 2017-02-17 | - | Bokslutskommuniké 2016 |
| 2016-05-20 | - | Kvartalsrapport 2016-Q3 |
| 2016-02-19 | - | Kvartalsrapport 2016-Q2 |
| 2015-12-03 | - | Årsstämma |
| 2015-09-18 | - | Bokslutskommuniké 2015 |
| 2015-05-21 | - | Kvartalsrapport 2015-Q3 |
| 2015-02-20 | - | Kvartalsrapport 2015-Q2 |
| 2014-12-04 | - | X-dag ordinarie utdelning IMMU 0.00 SEK |
| 2014-12-03 | - | Årsstämma |
| 2014-11-18 | - | Kvartalsrapport 2015-Q1 |
| 2014-09-17 | - | Bokslutskommuniké 2014 |
| 2014-05-07 | - | Kvartalsrapport 2014-Q3 |
| 2014-02-18 | - | Kvartalsrapport 2014-Q2 |
| 2013-12-04 | - | X-dag ordinarie utdelning IMMU 0.00 SEK |
| 2013-12-03 | - | Årsstämma |
| 2013-12-03 | - | Kvartalsrapport 2014-Q1 |
| 2013-09-10 | - | Bokslutskommuniké 2013 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Mendus AB (“Mendus” publ; IMMU.ST), will publish its interim report for the second quarter 2024 on August 23 at 08.00 CEST. The company will host a live presentation and business update on the same day at 10.00 CEST. The presentation will be held in English and includes a Q&A session.
Date and time: August 23 at 10.00 CEST
If you wish to participate via webcast please use the link below.
https://ir.financialhearings.com/mendus-q2-report-2024
If you wish to participate and ask questions via teleconference, please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference.
https://conference.financialhearings.com/teleconference/?id=50049744
For more information, please contact:
Erik Manting
Chief Executive Officer
E-mail: ir@mendus.com
About Mendus AB (publ)
Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving long-term survival for cancer patients, while preserving health and quality of life. We leverage our understanding of dendritic cell biology to develop an advanced clinical pipeline of immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. https://www.mendus.com/
Attachments
240815 Mendus 2Q 2024 Invite ENG